|
Following successful pilot trials of transplanting organs from hepatitis C virus viremic donors into HCV-negative recipients, there has been an expansion of the practice. Direct-acting antiviral therapies are costly, creating barriers to insurance coverage approvals, particularly in transplantation from HCV positive donors to HCV-negative recipients, due in part to off-label treatment of acute HCV following intentional HCV transmission.
|